Drug intelligence / Profile preview

EuBone

Development stage: Phase 4
Lead developer: Shandong University
Administration: Oral

Overview

EuBone is a traditional Chinese medicine (TCM) capsule formulation developed by Shandong University, specifically designed to address bone health in postmenopausal women. The formulation consists of a proprietary blend of three herbal extracts: *Eucommia ulmoides* extract, *Fructus ulmoides* extract, and dodder (*Cuscuta*) extract. It is primarily indicated for the prevention and treatment of osteopenia and osteoporosis by slowing bone mineral density loss and improving overall quality of life. The drug is currently undergoing Phase 4 clinical evaluation to confirm its long-term effectiveness and safety profile in postmenopausal populations.

Brand names: EuBone
Other names: EuBone capsule

Beyond the preview

Go deeper on EuBone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EuBone.

Explore the full profile